bupropion

(redirected from Bupropion HCl)
Also found in: Medical.

bu·pro·pi·on

 (byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

[bu(tyl) + propi(ophen)on(e), a ketone (propio(nic acid) + phen(yl) + -one).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

bupropion

(bjuːˈprəʊpɪɒn)
n
an antidepressant drug used to help people stop smoking
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

bupropion

n bupropión m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
This agreement allows Orexigen to sell the world-wide rights to Contrave (naltrexone HCl / bupropion HCl extended release) /Mysimba (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for USD75m in cash.
Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave (naltrexone HCl / bupropion HCl extended release) /Mysimba (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for USD 75m in cash.
Actavis has received approval from US Food and Drug Administration (US FDA) to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg.
(NASDAQ: OREX) wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Merck KGaA, Darmstadt, Germany have executed a distributorship agreement for Contrave (naltrexone HCl / bupropion HCl extended release) in Latin America, including Brazil and Mexico, the company said.
Biopharmaceutical company Orexigen Therapeutics Inc (Nasdaq:OREX) reported on Monday the launch of a distributorship agreement covering Denmark, Finland, Iceland, Norway and Sweden for Mysimba (naltrexone HCl / bupropion HCl prolonged release) for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
M2 EQUITYBITES-March 28, 2017-Orexigen Therapeutics signs distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Italy
In the US, the drug is approved as Contrave (naltrexone HCl / bupropion HCl extended release), added the company.
Biopharmaceutical company Orexigen Therapeutics Inc (NasdaqGS:OREX) revealed on Thursday the launch of a commercialisation and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland for the management of weight in adult patients.